Uncategorized
Trump’s FDA pick brings ‘relief,’ but ties to industry criticized
When President Donald J. Trump nominated Scott Gottlieb, MD, to be the next FDA commissioner, the announcement was met with relief by some that the agency’s scientific rigor would not be undermined but also warnings about Gottlieb’s deep ties to the pharmaceutical industry.Gottlieb, a past deputy commissioner at the FDA, has been a paid consultant for several pharmaceutical companies, reportedly accepting close to a half million dollars for his work.